ARTAN Bio Partners with Syenex VivoCell Platform for Precision in vivo Delivery of Next-Generation Codon Suppressors for Aging
HOUSTON and CHICAGO, June 30, 2025 /PRNewswire/ — ARTAN Bio, a community-backed biotechnology company developing therapeutics to reverse epigenetic changes associated with aging and age-related disease, and Syenex, an open-science genetic medicines platform company, today announced a strategic collaboration to access Syenex’s precision in vivo delivery technologies, the VivoCell Platform, for ARTAN’s lead drug, ARTAN-102. Under […]






